Several European countries are considering the possibility that citizens who have received the first dose of AstraZeneca vaccine will receive a second dose from another manufacturer due to problems caused by the British vaccine.
After being vaccinated with a small amount of rare blood clot in a few countries/regions, many countries/regions have stopped using the AstraZeneca vaccine for vaccination.
A senior official of the European Medicines Agency (EMA) said in an interview yesterday that there is a link between the vaccine and a rare blood clot in the brain, but the exact cause is not yet known.
EMA is still analyzing this vaccine. He will post updated comments later in the day.
AstraZeneca pointed out that her research showed that the risk of blood clots did not increase due to the vaccine provided to millions of people around the world. Many countries are still vaccinating AstraZeneca, but some countries have introduced age restrictions.
In many cases, officials now want to know what to do with people who receive the first dose of AstraZeneca vaccine, and under the new regulations, the second dose is not allowed. The number is small, but this decision is important because the combination of vaccines has not yet been tested. If there is any discrepancy with the official instructions of the EMA on the use of vaccines, countries should be responsible for possible side effects.
The European Medicines Agency did not comment on the question about the vaccine combination and mentioned a briefing to be held later in the day.
Some experts believe that these vaccines can be combined because they all target the same spike protein virus. But there is no evidence that this will be effective. Germany is the first European country to advise the first person under the age of 60 to receive the AstraZenecina vaccine from another manufacturer on April 1.
Norway will decide to continue to use AstraZeneca vaccine or other vaccines until April 15. Norwegian authorities are awaiting the results of a study launched by the United Kingdom in February that investigated the combination of Pfizer and AstraZeneca vaccines.
The UK decided last year to allow combined vaccines in rare cases, but it has not yet done so. Since March 29, Finland has been using the AstraZeneca vaccine. Finland has decided to only inject it into people over 65 and will wait for the conclusion of the EMA before issuing the recommendation. The second dose must start in mid-April.
In France, the AstraZeneca vaccine can only be administered to people over 55 years of age. People familiar with the matter said that relevant departments are considering the use of mRNA vaccines produced by Pfizer/BioNTech or Moderna for the second dose of treatment. Since more information, mainly from the UK, is awaiting, no formal decision has yet been made. The decision should be made in early May when the second dose of vaccine must be started.